Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and high-risk nonhospitalized patients with COVID-19 and in different age groups. Listen as David A. Wohl, MD, discusses when and how to use IV and oral antiviral agents including:
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases
Clinical Trials Unit
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
This program has been made available online.
Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)
Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)
Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)
Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)